Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

We knew when they started targeting transgender youth that eventually that would lead to them targeting transgender adults,” ...

After months of targeting transgender youth medical care, legislators are setting their sights on restrictions against care for transgender adults.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

For Mason Kalinsky, that would mean he may no longer be able to access the hormone therapy that he has been taking for roughly three years. Kalinsky, a 27-year-old transgender activist in Kentucky ...

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival ...